Stocktoria
Telomir Pharmaceuticals, Inc. TELO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-02-09
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Net income | -$10.4M | -$16.5M | -$13.1M | -$854,147 |
| Operating cash flow | -$3.7M | -$5.1M | -$3.9M | -$468,661 |
| Total assets | $7.3M | $1.3M | $4.8M | $48,730 |
| Total liabilities | $1.4M | $680,968 | $1.3M | $986,008 |
| Shareholders' equity | $5.9M | $643,037 | $3.4M | -$937,278 |
| Ratios | ||||
| Return on assets | -141.8% | -1248.7% | -273.8% | -1752.8% |
| Return on equity | -176.1% | -2571.0% | -380.2% | 91.1% |
| Current ratio | 5.14 | 1.94 | 0.33 | 0.05 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001971532 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.